RESUMEN
PURPOSE OF REVIEW: Life expectancy is increasing in cystic fibrosis and new aspects of the disease have to be taken into account in cystic fibrosis care. RECENT FINDINGS: Pain is encountered among 70% of adult and pediatric patients with cystic fibrosis. This symptom is underestimated by the multidisciplinary team. It has been reported as impacting quality of life and adherence to treatments. The location of pain is inconstant among the different studies but the major symptoms are headaches, gastrointestinal, and chest pain. Pain is different for each patient and requires careful evaluation using questionnaires some of which specifically developed for patients with cystic fibrosis. Medical and nonmedical treatment such as ostheopathy or sophrology may relieve pain symptoms but have to be adjusted in the frame of a global personalized care. SUMMARY: Pain maybe an underestimated symptom among patients with cystic fibrosis and impacts negatively on quality of life. VIDEO ABSTRACT.
Asunto(s)
Fibrosis Quística/complicaciones , Manejo del Dolor/métodos , Dimensión del Dolor/métodos , Dolor/etiología , Fibrosis Quística/terapia , Humanos , Dolor/diagnóstico , Calidad de Vida , Encuestas y CuestionariosAsunto(s)
Fibrosis Quística/diagnóstico , Cavidad Nasal/citología , Aminopiridinas/uso terapéutico , Benzodioxoles/uso terapéutico , Biomarcadores , Fibrosis Quística/tratamiento farmacológico , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Humanos , Mucosa Nasal/metabolismo , Resultado del TratamientoRESUMEN
RATIONALE: The use of long-term noninvasive respiratory support is increasing in children along with an extension of indications, in particular in children with central nervous system (CNS) disorders. OBJECTIVE: The aim of this study was to describe the characteristics of children with CNS disorders treated with long-term noninvasive respiratory support in France. METHODS: Data were collected from 27 French pediatric university centers through an anonymous questionnaire filled for every child treated with noninvasive ventilatory support ≥3 months on 1st June 2019. MAIN RESULTS: The data of 182 patients (55% boys, median age: 10.2 [5.4;14.8] years old [range: 0.3-25]) were collected: 35 (19%) patients had nontumoral spinal cord injury, 22 (12%) CNS tumors, 63 (35%) multiple disabilities, 26 (14%) central alveolar hypoventilation and 36 (20%) other CNS disorders. Seventy five percent of the patients were treated with noninvasive ventilation (NIV) and 25% with continuous positive airway pressure (CPAP). The main investigations performed before CPAP/NIV initiation were nocturnal gas exchange recordings, alone or coupled with poly(somno)graphy (in 29% and 34% of the patients, respectively). CPAP/NIV was started in an acute setting in 10% of the patients. Median adherence was 8 [6;10] hours/night, with 12% of patients using treatment <4 h/day. Nasal mask was the most common interface (70%). Airway clearance techniques were used by 31% of patients. CONCLUSION: CPAP/NIV may be a therapeutic option in children with CNS disorders. Future studies should assess treatment efficacy and patient reported outcome measures.
Asunto(s)
Enfermedades del Sistema Nervioso Central , Ventilación no Invasiva , Apnea Central del Sueño , Masculino , Niño , Humanos , Adolescente , Femenino , Ventilación no Invasiva/métodos , Presión de las Vías Aéreas Positiva Contínua/métodos , Resultado del Tratamiento , Enfermedades del Sistema Nervioso Central/complicaciones , Enfermedades del Sistema Nervioso Central/terapiaRESUMEN
The aim of the study was to describe the characteristics of children with neuromuscular diseases treated with long term noninvasive ventilation or continuous positive airway pressure in France. On June 1st 2019, 387 patients (63% boys, mean age 11.2 ± 5.5 years) were treated with long term noninvasive ventilation/continuous positive airway pressure. Thirty three percent of patients had spinal muscular atrophy, 30% congenital myopathy/dystrophy, 20% Duchenne muscular dystrophy, 7% Steinert myotonic dystrophy, and 9% other neuromuscular diseases. Ninety-four percent of patients were treated with long term noninvasive ventilation and 6% with continuous positive airway pressure. Treatment was initiated electively for 85% of patients, mainly on an abnormal overnight gas exchange recording (38% of patients). Noninvasive ventilation/continuous positive airway pressure was initiated during a respiratory exacerbation in 15% of patients. Mean duration of noninvasive ventilation/continuous positive airway pressure was 3.3 ± 3.1 years. Mean objective long term noninvasive ventilation/continuous positive airway pressure use was 8.0 ± 3.1 h/24. Spinal muscular atrophy, congenital myopathy/dystrophy, and Duchenne muscular dystrophy represented 83% of children with neuromuscular diseases treated with long term noninvasive ventilation in France. Screening for nocturnal hypoventilation was satisfactory as noninvasive ventilation /continuous positive airway pressure was predominantly initiated electively.
Asunto(s)
Atrofia Muscular Espinal , Distrofia Muscular de Duchenne , Enfermedades Neuromusculares , Ventilación no Invasiva , Masculino , Niño , Humanos , Preescolar , Adolescente , Femenino , Presión de las Vías Aéreas Positiva Contínua , Distrofia Muscular de Duchenne/complicaciones , Distrofia Muscular de Duchenne/terapia , Enfermedades Neuromusculares/complicaciones , Enfermedades Neuromusculares/terapiaRESUMEN
Background: The combination of the CFTR corrector lumacaftor (LUM) and potentiator ivacaftor (IVA) has been labeled in France since 2015 for F508del homozygote cystic fibrosis (CF) patients over 12 years. In this real-life study, we aimed (i) to compare the changes in lung function, clinical (e.g., body mass index and pulmonary exacerbations) and radiological parameters, and in sweat chloride concentration before and after initiation of LUM/IVA treatment; (ii) to identify factors associated with response to treatment; and (iii) to assess the tolerance to treatment. Materials and Methods: In this tri-center, non-interventional, and observational cohort study, children (12-18 years old) were assessed prospectively during the 2 years of therapy, and retrospectively during the 2 years preceding treatment. Data collected and analyzed for the study were exclusively extracted from the medical electronic system records of the patients. Results: Forty adolescents aged 12.0-17.4 years at LUM/IVA initiation were included. The lung function decreased significantly during and prior to treatment and increased after LUM/IVA initiation, becoming significant after 2 years of treatment. LUM/IVA significantly improved the BMI Z-score and sweat chloride concentration. By contrast, there was no significant change in exacerbation rates, antibiotic use, or CT scan scores. Age at LUM/IVA initiation was lower in good responders and associated with greater ppFEV1 change during the 2 years of treatment. LUM/IVA was well-tolerated. Conclusion: In F508del homozygote adolescents, real-life long-term LUM/IVA improved the ppFEV1 trajectory, particularly in the youngest patients, nutritional status, and sweat chloride concentration but not exacerbation rates or radiological scores. LUM/IVA was generally well-tolerated and safe.
RESUMEN
OBJECTIVE: To describe the characteristics of children treated with long term continuous positive airway pressure (CPAP) or noninvasive ventilation (NIV) in France. DESIGN: Cross-sectional national survey. SETTING: Paediatric CPAP/NIV teams of 28 tertiary university hospitals in France. PATIENTS: Children aged <20 years treated with CPAP/NIV since at least 3 months on June 1st, 2019. INTERVENTION: An anonymous questionnaire was filled in for every patient. RESULTS: The data of 1447 patients (60% boys), mean age 9.8 ± 5.8 years were analysed. The most frequent underlying disorders were: upper airway obstruction (46%), neuromuscular disease (28%), disorder of the central nervous system (13%), cardiorespiratory disorder (7%), and congenital bone disease (4%). Forty-five percent of the patients were treated with CPAP and 55% with NIV. Treatment was initiated electively for 92% of children, while 8% started during an acute illness. A poly(somno)graphy (P(S)G) was performed prior to treatment initiation in 26%, 36% had a P(S)G with transcutaneous carbon dioxide monitoring (PtcCO2), while 23% had only a pulse oximetry (SpO2) with PtcCO2 recording. The decision of CPAP/NIV initiation during an elective setting was based on the apnea-hypopnea index (AHI) in 41% of patients, SpO2 and PtcCO2 in 25% of patients, and AHI with PtcCO2 in 25% of patients. Objective adherence was excellent with a mean use of 7.6 ± 3.2 h/night. Duration of CPAP/NIV was 2.7 ± 2.9 years at the time of the survey. CONCLUSION: This survey shows the large number of children treated with long term CPAP/NIV in France with numerous children having disorders other than neuromuscular diseases.
Asunto(s)
Presión de las Vías Aéreas Positiva Contínua , Ventilación no Invasiva , Adolescente , Factores de Edad , Obstrucción de las Vías Aéreas/terapia , Niño , Preescolar , Presión de las Vías Aéreas Positiva Contínua/estadística & datos numéricos , Estudios Transversales , Femenino , Francia/epidemiología , Humanos , Lactante , Masculino , Ventilación no Invasiva/estadística & datos numéricos , Cooperación del Paciente/estadística & datos numéricos , Síndromes de la Apnea del Sueño/terapia , Encuestas y Cuestionarios , Factores de Tiempo , Adulto JovenRESUMEN
BACKGROUND: Ivacaftor-lumacaftor combination therapy corrects the F508 del-CFTR mutated protein which causes Cystic Fibrosis. The clinical response of the patients treated with the combination therapy is highly variable. This study aimed to determine factors involved in the individual's response to lumacaftor-ivacaftor therapy. METHODS: Sweat test was assessed at baseline and after 6â¯months of ivacaftor-lumacaftor treatment in 41 homozygous F508del children and young adults. ß-adrenergic peak sweat secretion, nasal potential difference (NPD) and intestinal current measurements (ICM) were performed in patients accepting these tests. Seric level of lumacaftor and ivacaftor were determined and additional CFTR variant were searched. RESULTS: Sweat chloride concentration significantly decreased after treatment, whereas the ß-adrenergic peak sweat response did not vary in 9 patients who underwent these tests. The average level of F508del-CFTR activity rescue reached up to 15% of the normal level in intestinal epithelium, as studied by ICM in 12 patients (pâ¯=â¯.03) and 20% of normal in the nasal epithelium in NPD tests performed in 21 patients (NS). There was no significant correlation between these changes and improvements in FEV1 at 6â¯months. Serum drug levels did not correlate with changes in FEV1, BMI-Zscore or other CFTR activity biomarkers. Additional exonic variants were identified in 4 patients. The F87L-I1027T-F508del-CFTR complex allele abolished the lumacaftor corrector effect. CONCLUSION: This observational study investigates a number of potential factors linked to the clinical response of F508del homozygous patients treated with lumacaftor-ivacaftor combination therapy. Lumacaftor and ivacaftor blood levels are not associated with the clinical response. Additional exonic variants may influence protein correction.
Asunto(s)
Aminofenoles , Aminopiridinas , Benzodioxoles , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Fibrosis Quística , Monitoreo de Drogas/métodos , Quinolonas , Sudor , Aminofenoles/administración & dosificación , Aminofenoles/efectos adversos , Aminofenoles/farmacocinética , Aminopiridinas/administración & dosificación , Aminopiridinas/efectos adversos , Aminopiridinas/farmacocinética , Benzodioxoles/administración & dosificación , Benzodioxoles/efectos adversos , Benzodioxoles/farmacocinética , Biomarcadores Farmacológicos , Niño , Agonistas de los Canales de Cloruro/administración & dosificación , Agonistas de los Canales de Cloruro/efectos adversos , Agonistas de los Canales de Cloruro/farmacocinética , Fibrosis Quística/diagnóstico , Fibrosis Quística/tratamiento farmacológico , Fibrosis Quística/genética , Combinación de Medicamentos , Femenino , Humanos , Masculino , Mutación , Pruebas de Farmacogenómica , Quinolonas/administración & dosificación , Quinolonas/efectos adversos , Quinolonas/farmacocinética , Pruebas de Función Respiratoria/métodos , Sudor/química , Sudor/metabolismo , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Hospitalisation for an acute bronchiolitis might lead to unwanted weaning off breast feeding for several reasons (respiratory distress, use of enteral or parenteral feeding, mothers tiredness, among others), yet it has never been really evaluated or quantified. METHODS: We conducted this telephone survey to evaluate breastfeeding disruption during hospitalisation for bronchiolitis and try to identify its determining factors for future interventions. This cross-sectional study extends over one epidemic season of bronchiolitis in a tertiary care hospital. All patients aged 6 months or younger hospitalised with acute bronchiolitis and receiving at least partial breast feeding were eligible for the study (n=144). Patients discharged home whose parents accepted to be contacted for a phone survey were included. Parents were contacted 3 months (range 0.5-6) after discharge. RESULTS: Eighty-four patients were included in the study. Median length of hospital stay was 3 days (1; 34), and 27 patients spent some time in paediatric intensive care unit. Forty-three mothers stated that hospitalisation modified their breast feeding (17 stopped, 12 switched to partial breast feeding and 14 reduced without stopping). Mothers stated that the causes of breastfeeding disturbance were lack of support and advices (n=27) followed by child's respiratory disease (n=14), logistic hospital difficulties (n=13) and personal organisation issues (n=4). CONCLUSION: Admission to hospital with bronchiolitis may adversely affect breast feeding. Correct advices and support could be a determining factor, and further studies should focus on preventive interventions.